Page 145, line 25 after "gccgccgccATG" insert --(SEQ ID NO.: 103)--.

Page 145, line 26 after "3'" insert --(SEQ ID NO.: 104)--.

IN THE CLAIMS:

Cancel claims 1-70 without prejudice to Applicants' right to further prosecute claims of the same or similar scope in duly filed continuation, continuation-in-part and/or divisional applications.

Enter claims 71-114 as follows:

--71. A composition which comprises a therapeutically effective amount of stem cell factor (SCF) polypeptide or biologically active fragment or analog thereof and one or more cytokines in a pharmaceutically acceptable carrier.

72. The composition of claim 71, wherein SCF polypeptide is a product of a recombinant prokaryote cell or eukaryote cells.

73. The composition of claim 72, wherein the SCF polypeptide is a human SCF polypeptide.

74. The composition of claim 73, wherein the SCF polypeptide is selected from the group of polypeptides consisting of the amino acid sequence set out as 1-162, 1-164 and 1-165 as set out in Figure 15C, said polypeptides optionally consisting of an N-terminal methionine.

75. The composition of claim 73, wherein the SCF polypeptide is selected from the group of polypeptides consisting of the amino acid sequence set out as 1-100, 1-110, 1-120, 1-123, 1-127, 1-130, 1-133, 1-137, 1-141, 1-145, 1-148, 1-152, 1-156, 1-157, 1-158, 1-159, 1-160, 1-161, 1-163, 1-166, 1-168, 1-173, 1-178, 2-164, 2-165, 5-164, 11-

164, 1-180, 1-183, 1-185, 1-188, 1-189, 1-220 and 1-248 as set out in Figures 42A-C, said polypeptide optionally consisting of an N-terminal methionine.

76. The composition of claim 73, wherein the SCF polypeptide is selected from the group consisting of amino acids 1-152, 1-157, 1-160, 1-161 and 1-220 as set out in Figures 44A-C, said polypeptide optionally consisting of N-terminal methionine.

77. The method of claims 74, 75, or 76, wherein the stem cell factor is covalently conjugated to a water-soluble polymer.

78. The method of claim 77, wherein the water soluble polymer is polyethylene glycol.

79. The composition of claim 74, 75, or 76, wherein the amount of SCF in the composition is effective to treat hematopoietic disorders.

80. The composition of claim 77, wherein the amount of SCF in the composition is effective to treat hematopoietic disorders.

81. The composition of claim 74, 75, or 76, wherein the amount of SCF in the composition is effective to treat epithelial cell disorders.

82. The composition of claim 77 wherein the amount of SCF in the composition is effective to treat epithelial cell disorders.

83. The composition of claim 74, 75, or 76, wherein the amount of SCF in the composition is effective to treat stromal cell disorders.

84. The composition of claim 77, wherein the amount of SCF in the composition is effective to treat stromal cell disorders.

85. The composition of claim 74, 75, or 76, wherein the amount of SCF in the composition is effective to treat neural disorders.

86. The composition of claim 77, wherein the amount of SCF in the composition is effective to treat neural disorders.

87. The composition of claim 74, 75, or 76, wherein the amount of SCF in the composition is effective to treat pigmentation disorders.

88. The composition of claim 77, wherein the amount of SCF in the composition is effective to treat pigmentation disorders.

89. The composition of claim 74, 75, or 76, wherein the amount of SCF in the composition is effective to treat germ cell disorders.

90. The composition of claim 77, wherein the amount of SCF in the composition is effective to treat germ cell disorders.

91. The composition of claim 79, wherein the composition contains at least one cytokine selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, GM-CSF, CSF-1, IGF-1, and LIF.

92. The composition of claim 80, wherein the composition contains at least one cytokine selected from the group consisting of IL-1, Il-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, GM-CSF, CSF-1, IGF-1, and LIF.

93. The composition of claim 81, wherein the composition contains at least one cytokine selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, GM-CSF, CSF-1, IGF-1, and LIF.

94. The composition of claim 82, wherein the composition contains at least one cytokine selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, GM-CSF, CSF-1, IGF-1, and LIF.

95. The composition of claim 83, wherein the composition contains at least one cytokine selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, GM-CSF, CSF-1, IGF-1, and LIF.

96. The composition of claim 84, wherein the composition contains at least one cytokine selected from the group consisting of IL-1, Il-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, GM-CSF, CSF-1, IGF-1, and LIF.

97. The composition of claim 85, wherein the composition contains at least one cytokine selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, GM-CSF, CSF-1, IGF-1, and LIF.

98. The composition of claim 86, wherein the composition contains at least one cytokine selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, GM-CSF, CSF-1, IGF-1, and LIF.

99. The composition of claim 87, wherein the composition contains at least one cytokine selected from the group consisting of IL-1, Il-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, GM-CSF, CSF-1, IGF-1, and LIF.

100. The composition of claim 88, wherein the composition contains at least one cytokine selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, GM-CSF, CSF-1, IGF-1, and LIF.

101. The composition of claim 89, wherein the composition contains at least one cytokine selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, GM-CSF, CSF-1, IGF-1, and LIF.

102. The composition of claim 90, wherein the composition contains at least one cytokine selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, GM-CSF, CSF-1, IGF-1, and LIF.

103. The composition of claim 74, 75, or 76, wherein the composition contains a pharmaceutically effective carrier for the controlled release of SCF and other cytokines in the composition.

104. The composition of claim 77, wherein the composition contains a pharmaceutically effective carrier for the controlled release of SCF and other cytokines in the composition

105. The composition of claim 74, 75, or 76, wherein the composition contains a pharmaceutically effective carrier for parenteral delivery of the composition.

106. The composition of claim 77, wherein the composition contains a pharmaceutically effective carrier for parenteral delivery of the composition.

107. The composition of claim 74, 75, or 76, wherein the composition contains a pharmaceutically effective carrier for pulmonary delivery of the composition.

108. The composition of claim 77, wherein the composition contains a pharmaceutically effective carrier for pulmonary delivery of the composition.

109. The composition of claim 74, 75, or 76, wherein the composition contains a pharmaceutically effective carrier for nasal delivery of the composition.

110. The composition of claim 77, wherein the composition contains a pharmaceutically effective carrier for nasal delivery of the composition.